Pharmacologic magnetic resonance imaging (phMRI): Imaging drug action in the brain

NeuroImage

Volumn 62, Issue 2, 2012, Pages 1072-1085

  Jenkins, Bruce G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Drugs; FMRI; Hemodynamics; Neurotransmitters; PhMRI; Receptor

Indexed keywords

AMPHETAMINE; COCAINE; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; GADOLINIUM PENTETATE; LEVODOPA; NICOTINE;

AUTORADIOGRAPHY; BOLD SIGNAL; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG MECHANISM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INTERMETHOD COMPARISON; INTRACELLULAR SIGNALING; LIGAND BINDING; MOLECULAR IMAGING; NEUROIMAGING; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PHARMACOLOGIC MAGNETIC RESONANCE IMAGING; PHARMACOLOGICAL BLOCKING; PLASMA CONCENTRATION-TIME CURVE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALS; BRAIN; BRAIN MAPPING; HEMODYNAMICS; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 84863009508     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.03.075     Document Type: Review

References (137)

1. Amenta F., Barili P., Bronzetti E., Felici L., Mignini F., Ricci A. Localization of dopamine receptor subtypes in systemic arteries. Clin. Exp. Hypertens. 2000, 22:277-288.
2. Anand A., Li Y., Wang Y., Wu J., Gao S., Bukhari L., Mathews V.P., Kalnin A., Lowe M.J. Antidepressant effect on connectivity of the mood-regulating circuit: an FMRI study. Neuropsychopharmacology 2005, 30:1334-1344.
3. Anderson I.M., McKie S., Elliott R., Williams S.R., Deakin J.F. Assessing human 5-HT function in vivo with pharmacoMRI. Neuropharmacology 2008, 55:1029-1037.
4. Attwell D., Buchan A.M., Charpak S., Lauritzen M., Macvicar B.A., Newman E.A. Glial and neuronal control of brain blood flow. Nature 2010, 468:232-243.
5. Bandettini P.A., Wong E.C., Hinks R.S., Tikofsky R.S., Hyde J.S. Time course EPI of human brain function during task activation. Magn. Reson. Med. 1992, 25:390-397.
6. Belliveau J.W., Kennedy D.N., McKinstry R.C., Buchbinder B.R., Weisskoff R.M., Cohen M.S., Vevea J.M., Brady T.J., Rosen B.R. Functional mapping of the human visual cortex by magnetic resonance imaging. Science 1991, 254:716-719.
7. Bjorklund L.M., Sanchez-Pernaute R., Chung S., Andersson T., Chen I.Y., McNaught K.S., Brownell A.L., Jenkins B.G., Wahlestedt C., Kim K.S., Isacson O. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:2344-2349.
8. Bloom A.S., Hoffmann R.G., Fuller S.A., Pankiewicz J., Harsch H.H., Stein E.A. Determination of drug-induced changes in functional MRI signal using a pharmacokinetic model. Hum. Brain Mapp. 1999, 8:235-244.
9. Borsook D., Hargreaves R., Becerra L. Can functional magnetic resonance imaging improve success rates in CNS drug discovery?. Expert Opin. Drug Discov 2011, 6:597-617.
10. Bossong M.G., Jager G., van Hell H.H., Zuurman L., Jansma J.M., Mehta M.A., vanGerven J.M., Kahn R.S., Ramsey N.F. Effects of delta9-tetrahydrocannabinol administration on human encoding and recall memory function: a pharmacological fMRI study. J. Cogn. Neurosci. 2012, 24(3):588-599.
11. Buckner R.L., Vincent J.L. Unrest at rest: default activity and spontaneous network correlations. NeuroImage 2007, 37:1091-1096. discussion 1097-1099.
12. Burke M., Buhrle C. BOLD response during uncoupling of neuronal activity and CBF. NeuroImage 2006, 32:1-8.
13. Canese R., Marco E.M., De Pasquale F., Podo F., Laviola G., Adriani W. Differential response to specific 5-Ht(7) versus whole-serotonergic drugs in rat forebrains: a phMRI study. NeuroImage 2011, 58:885-894.
14. Carlsson C., Hagerdal M., Siesjo B.K. Influence of amphetamine sulfate on cerebral blood flow and metabolism. Acta Physiol. Scand. 1975, 94:128-129.
15. Cavanna A.E., Trimble M.R. The precuneus: a review of its functional anatomy and behavioural correlates. Brain 2006, 129:564-583.
16. Chen Q., Andersen A.H., Zhang Z., Ovadia A., Gash D.M., Avison M.J. Mapping drug-induced changes in cerebral R2* by multiple gradient recalled echo functional MRI. Magn. Reson. Imaging 1996, 14:469-476.
17. Chen Y.C., Galpern W.R., Brownell A.L., Matthews R.T., Bogdanov M., Isacson O., Keltner J.R., Beal M.F., Rosen B.R., Jenkins B.G. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn. Reson. Med. 1997, 38:389-398.
18. Chen Y.I., Brownell A.L., Galpern W., Isacson O., Bogdanov M., Beal M.F., Livni E., Rosen B.R., Jenkins B.G. Detection of dopaminergic cell loss and neural transplantation using pharmacological MRI, PET and behavioral assessment. Neuroreport 1999, 10:2881-2886.
19. Chen Y.C., Choi J.K., Andersen S.L., Rosen B.R., Jenkins B.G. Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging. Psychopharmacology (Berl) 2005, 180:705-715.
20. Chen Y.I., Choi J.K., Jenkins B.G. Mapping interactions between dopamine and adenosine A2a receptors using pharmacologic MRI. Synapse 2005, 55:80-88.
21. Chen Y.I., Choi J.K., Xu H., Ren J., Andersen S.L., Jenkins B.G. Pharmacologic neuroimaging of the ontogeny of dopamine receptor function. Dev. Neurosci. 2010, 32:125-138.
22. Chen Y.I., Famous K., Xu H., Choi J.K., Mandeville J.B., Schmidt H.D., Pierce R.C., Jenkins B.G. Cocaine self-administration leads to alterations in temporal responses to cocaine challenge in limbic and motor circuitry. Eur. J. Neurosci. 2011, 34:800-815.
23. Chin C.L., Tovcimak A.E., Hradil V.P., Seifert T.R., Hollingsworth P.R., Chandran P., Zhu C.Z., Gauvin D., Pai M., Wetter J., Hsieh G.C., Honore P., Frost J.M., Dart M.J., Meyer M.D., Yao B.B., Cox B.F., Fox G.B. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br. J. Pharmacol. 2008, 153:367-379.
24. Choi J.K., Chen Y.I., Hamel E., Jenkins B.G. Brain hemodynamic changes mediated by dopamine receptors: role of the cerebral microvasculature in dopamine-mediated neurovascular coupling. NeuroImage 2006, 30:700-712.
25. Choi J.K., Mandeville J.B., Chen Y.I., Kim Y.R., Jenkins B.G. High resolution spatial mapping of nicotine action using pharmacologic magnetic resonance imaging. Synapse 2006, 60:152-157.
26. Choi J.K., Mandeville J.B., Chen Y.I., Grundt P., Sarkar S.K., Newman A.H., Jenkins B.G. Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists. Psychopharmacology (Berl) 2010, 212:59-72.
27. Cohen Z., Bonvento G., Lacombe P., Hamel E. Serotonin in the regulation of brain microcirculation. Prog. Neurobiol. 1996, 50:335-362.
28. Delfino M., Kalisch R., Czisch M., Larramendy C., Ricatti J., Taravini I.R., Trenkwalder C., Murer M.G., Auer D.P., Gershanik O.S. Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology 2007, 32:1911-1921.
29. Dewey S.L., Smith G.S., Logan J., Brodie J.D., Simkowitz P., MacGregor R.R., Fowler J.S., Volkow N.D., Wolf A.P. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:11816-11820.
30. Dixon A.L., Prior M., Morris P.M., Shah Y.B., Joseph M.H., Young A.M. Dopamine antagonist modulation of amphetamine response as detected using pharmacological MRI. Neuropharmacology 2005, 48:236-245.
31. Dodd G.T., Stark J.A., McKie S., Williams S.R., Luckman S.M. Central cannabinoid signaling mediating food intake: a pharmacological-challenge magnetic resonance imaging and functional histology study in rat. Neuroscience 2009, 163:1192-1200.
32. Dodds C.M., Clark L., Dove A., Regenthal R., Baumann F., Bullmore E., Robbins T.W., Muller U. The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD signal during the manipulation of information in working memory. Psychopharmacology (Berl) 2009, 207:35-45.
33. Dolan R.J., Grasby P.M., Bench C., Friston K.J., Frith C.D. Pharmacological challenge and PET imaging. Clin. Neuropharmacol. 1992, Suppl 1(Pt A):216A-217A.
34. Elhusseiny A., Hamel E. Muscarinic - but not nicotinic - acetylcholine receptors mediate a nitric oxide-dependent dilation in brain cortical arterioles: a possible role for the M5 receptor subtype. J. Cereb. Blood Flow Metab. 2000, 20:298-305.
35. Ersche K.D., Bullmore E.T., Craig K.J., Shabbir S.S., Abbott S., Muller U., Ooi C., Suckling J., Barnes A., Sahakian B.J., Merlo-Pich E.V., Robbins T.W. Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence. Arch. Gen. Psychiatry 2010, 67:632-644.
36. Fillenz M., Lowry J.P., Boutelle M.G., Fray A.E. The role of astrocytes and noradrenaline in neuronal glucose metabolism. Acta Physiol. Scand. 1999, 167:275-284.
37. Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., Macgregor R.R., Hitzemann R., Logan J., Bendriem B., Gatley S.J., et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 1989, 4:371-377.
38. Fowler J.S., Volkow N.D., MacGregor R.R., Logan J., Dewey S.L., Gatley S.J., Wolf A.P. Comparative PET studies of the kinetics and distribution of cocaine and cocaethylene in baboon brain. Synapse 1992, 12:220-227.
39. Friston K.J., Grasby P.M., Bench C.J., Frith C.D., Cowen P.J., Liddle P.F., Frackowiak R.S., Dolan R. Measuring the neuromodulatory effects of drugs in man with positron emission tomography. Neurosci. Lett. 1992, 141:106-110.
40. Goekoop R., Scheltens P., Barkhof F., Rombouts S.A. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation - a pharmacological fMRI study. Brain 2006, 129:141-157.
41. Gozzi A., Schwarz A.J., Reese T., Crestan V., Bertani S., Turrini G., Corsi M., Bifone A. Functional magnetic resonance mapping of intracerebroventricular infusion of a neuroactive peptide in the anaesthetised rat. J. Neurosci. Methods 2005, 142:115-124.
42. Gozzi A., Schwarz A., Reese T., Bertani S., Crestan V., Bifone A. Region-specific effects of nicotine on brain activity: a pharmacological MRI study in the drug-naive rat. Neuropsychopharmacology 2006, 31:1690-1703.
43. Gozzi A., Ceolin L., Schwarz A., Reese T., Bertani S., Crestan V., Bifone A. A multimodality investigation of cerebral hemodynamics and autoregulation in pharmacological MRI. Magn. Reson. Imaging 2007, 25:826-833.
44. Gozzi A., Herdon H., Schwarz A., Bertani S., Crestan V., Turrini G., Bifone A. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. Psychopharmacology (Berl) 2008, 201:273-284.
45. Gozzi A., Large C.H., Schwarz A., Bertani S., Crestan V., Bifone A. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 2008, 33:1690-1703.
46. Grundt P., Prevatt K.M., Cao J., Taylor M., Floresca C.Z., Choi J.K., Jenkins B.G., Luedtke R.R., Newman A.H. Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J. Med. Chem. 2007, 50:4135-4146.
47. Gsell W., Burke M., Wiedermann D., Bonvento G., Silva A.C., Dauphin F., Buhrle C., Hoehn M., Schwindt W. Differential effects of NMDA and AMPA glutamate receptors on functional magnetic resonance imaging signals and evoked neuronal activity during forepaw stimulation of the rat. J. Neurosci. 2006, 26:8409-8416.
48. Gulbenkian S., Uddman R., Edvinsson L. Neuronal messengers in the human cerebral circulation. Peptides 2001, 22:995-1007.
49. Head R.J., Hjelle J.T., Jarrott B., Berkowitz B., Cardinale G., Spector S. Isolated brain microvessels: preparation, morphology, histamine and catecholamine contents. Blood Vessels 1980, 17:173-186.
50. Hoff E.I., van Oostenbrugge R.J., Otte W.M., van der Marel K., Steinbusch H.W., Dijkhuizen R.M. Pharmacological magnetic resonance imaging of muscarinic acetylcholine receptor activation in rat brain. Neuropharmacology 2010, 58:1252-1257.
51. Honey G.D., Suckling J., Zelaya F., Long C., Routledge C., Jackson S., Ng V., Fletcher P.C., Williams S.C., Brown J., Bullmore E.T. Dopaminergic drug effects on physiological connectivity in a human cortico-striato-thalamic system. Brain 2003, 126:1767-1781.
52. Hong L.E., Gu H., Yang Y., Ross T.J., Salmeron B.J., Buchholz B., Thaker G.K., Stein E.A. Association of nicotine addiction and nicotine's actions with separate cingulate cortex functional circuits. Arch. Gen. Psychiatry 2009, 66:431-441.
53. Houston G.C., Papadakis N.G., Carpenter T.A., Hall L.D., Mukherjee B., James M.F., Huang C.L. Mapping of brain activation in response to pharmacological agents using fMRI in the rat. Magn. Reson. Imaging 2001, 19:905-919.
54. Iadecola C. Regulation of the cerebral microcirculation during neural activity: is nitric oxide the missing link?. Trends Neurosci. 1993, 16:206-214.
55. Jacobsen L.K., D'Souza D.C., Mencl W.E., Pugh K.R., Skudlarski P., Krystal J.H. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol. Psychiatry 2004, 55:850-858.
56. Jakovcevic D., Harder D.R. Role of astrocytes in matching blood flow to neuronal activity. Curr. Top. Dev. Biol. 2007, 79:75-97.
57. Jenkins B.G., Chen I.Y., Mandeville J.B. Pharmacologic magnetic resonance imaging (phMRI). Biomedical Imaging in Experimental Neuroscience 2002, 155-209. CRC Press, Boca Raton, FL. N. van Bruggen, T. R. (Eds.).
58. Jenkins B.G., Sanchez-Pernaute R., Brownell A.L., Chen Y.C., Isacson O. Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J. Neurosci. 2004, 24:9553-9560.
59. Jenkins B.G., Choi J.-K., Mandeville J.B., Chen Y. Brain fMRI in pre-clinical pharmacological stimulation studies. Pharmacology and Toxicology: Basic and Clinical Aspects: In Vivo MR Techniques in Drug Discovery and Development 2006, CRC Press, Boca Raton, FL, p. Chap. 8. N. Beckmann (Ed.).
60. Jenkins B.G., Hamamcia A., Chen Y., Mandeville J.B., Choi J.-K. Quantitative Measurements of Dopamine Release and Uptake using pharmacologic MRI 2007, ISMRM, Berlin, Germany, p. 437.
61. Jones B.E. Relationship between catecholamine neurons and cerebral blood vessels studied by their simultaneous fluorescent revelation in the rat brainstem. Brain Res. Bull. 1982, 9:33-44.
62. Jones N., O'Neill M.J., Tricklebank M., Libri V., Williams S.C. Examining the neural targets of the AMPA receptor potentiator LY404187 in the rat brain using pharmacological magnetic resonance imaging. Psychopharmacology (Berl) 2005, 180:743-751.
63. Jones N., Messenger M.J., O'Neill M.J., Oldershaw A., Gilmour G., Simmons R.M., Iyengar S., Libri V., Tricklebank M., Williams S.C. AMPA receptor potentiation can prevent ethanol-induced intoxication. Neuropsychopharmacology 2008, 33:1713-1723.
64. Khalili-Mahani N., Zoethout R.M., Beckmann C.F., Baerends E., de Kam M.L., Soeter R.P., Dahan A., van Buchem M.A., van Gerven J.M., Rombouts S.A. Effects of morphine and alcohol on functional brain connectivity during "resting state": a placebo-controlled crossover study in healthy young men 2011, Hum Brain Mapp.
65. Kimberg D.Y., Aguirre G.K., Lease J., D'Esposito M. Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI. Hum. Brain Mapp. 2001, 12:246-257.
66. Klomp A., Tremoleda J.L., Wylezinska M., Nederveen A.J., Feenstra M., Gsell W., Reneman L. Lasting effects of chronic fluoxetine treatment on the late developing rat brain: age-dependent changes in the serotonergic neurotransmitter system assessed by pharmacological MRI. NeuroImage 2012, 59:218-226.
67. Kobiella A., Ulshofer D.E., Vollmert C., Vollstadt-Klein S., Buhler M., Esslinger C., Smolka M.N. Nicotine increases neural response to unpleasant stimuli and anxiety in non-smokers. Addict. Biol. 2011, 16:285-295.
68. Krimer L.S., Muly E.C., Williams G.V., Goldman-Rakic P.S. Dopaminergic regulation of cerebral cortical microcirculation. Nat. Neurosci. 1998, 1:286-289.
69. Kuhl D.E., Alavi A., Reivich M., Edwards R.Q., Fenton C.A., Zimmerman R.A. Emission Computerized-Tomography and Determination of Local Brain Function 1975.
70. Kuhl D.E., Phelps M.E., Hoffman E.J., Robinson G.D., MacDonald N.S. Initial clinical experience with 18F-2-fluoro-2-deoxy-d-glucose for determination of local cerebral glucose utilization by emission computed tomography. Acta Neurol. Scand. Suppl. 1977, 64:192-193.
71. Kwong K.K., Belliveau J.W., Chester D.A., Coldberg I.E., Weisskoff R.M., Poncelet B.P., Kennedy D.N., Hoppel B.E., Cohen M.S., Turner R., Cheng H.M., Brady T.J., Rosen B.R. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:5675-5679.
72. Lauritzen M. Reading vascular changes in brain imaging: is dendritic calcium the key?. Nat. Rev. Neurosci. 2005, 6:77-85.
73. Lauritzen M., Mathiesen C., Schaefer K., Thomsen K.J. Neuronal Inhibition and Excitation, and the Dichotomic Control of Brain Hemodynamic and Oxygen Responses 2012, Neuroimage.
74. Leslie R.A., James M.F. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol. Sci. 2000, 21:314-318.
75. Li S.J., Biswal B., Li Z., Risinger R., Rainey C., Cho J.K., Salmeron B.J., Stein E.A. Cocaine administration decreases functional connectivity in human primary visual and motor cortex as detected by functional MRI. Magn. Reson. Med. 2000, 43:45-51.
76. Li W., Antuono P.G., Xie C., Chen G., Jones J.L., Ward B.D., Franczak M.B., Goveas J.S., Li S.J. Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment. NeuroImage 2012, 60:1083-1091.
77. Lindauer U., Villringer A., Dirnagl U. Characterization of CBF response to somatosensory stimulation: model and influence of anesthetics. Am. J. Physiol. 1993, 264:H1223-H1228.
78. Littlewood C.L., Cash D., Dixon A.L., Dix S.L., White C.T., O'Neill M.J., Tricklebank M., Williams S.C. Using the BOLD MR signal to differentiate the stereoisomers of ketamine in the rat. NeuroImage 2006, 32:1733-1746.
79. Littlewood C.L., Jones N., O'Neill M.J., Mitchell S.N., Tricklebank M., Williams S.C. Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology (Berl) 2006, 186:64-81.
80. Liu C.H., D'Arceuil H.E., de Crespigny A.J. Direct CSF injection of MnCl(2) for dynamic manganese-enhanced MRI. Magn. Reson. Med. 2004, 51:978-987.
81. Liu C.H., Greve D.N., Dai G., Marota J.J., Mandeville J.B. Remifentanil administration reveals biphasic phMRI temporal responses in rat consistent with dynamic receptor regulation. NeuroImage 2007, 34:1042-1053.
82. Luo F., Schmidt K.F., Fox G.B., Ferris C.F. Differential responses in CBF and CBV to cocaine as measured by fMRI: implications for pharmacological MRI signals derived oxygen metabolism assessment. J. Psychiatr. Res. 2009, 43:1018-1024.
83. Mandeville J.B., Choi J.K., Jarraya B., Rosen B.R., Jenkins B.G., Vanduffel W. FMRI of cocaine self-administration in macaques reveals functional inhibition of basal ganglia. Neuropsychopharmacology 2011, 36:1187-1198.
84. Marota J.J., Mandeville J.B., Weisskoff R.M., Moskowitz M.A., Rosen B.R., Kosofsky B.E. Cocaine activation discriminates dopaminergic projections by temporal response: an fMRI study in Rat. NeuroImage 2000, 11:13-23.
85. Martin C., Sibson N.R. Pharmacological MRI in animal models: a useful tool for 5-HT research?. Neuropharmacology 2008, 55:1038-1047.
86. McMahon M.T., Gilad A.A., Zhou J., Sun P.Z., Bulte J.W., van Zijl P.C. Quantifying exchange rates in chemical exchange saturation transfer agents using the saturation time and saturation power dependencies of the magnetization transfer effect on the magnetic resonance imaging signal (QUEST and QUESP): Ph calibration for poly-l-lysine and a starburst dendrimer. Magn. Reson. Med. 2006, 55:836-847.
87. Menon R.S., Ogawa S., Hu X., Strupp J.P., Anderson P., Ugurbil K. BOLD based functional MRI at 4 Tesla includes a capillary bed contribution: echo-planar imaging correlates with previous optical imaging using intrinsic signals. Magn. Reson. Med. 1995, 33:453-459.
88. Meunier D., Ersche K.D., Craig K.J., Fornito A., Merlo-Pich E., Fineberg N.A., Shabbir S.S., Robbins T.W., Bullmore E.T. Brain functional connectivity in stimulant drug dependence and obsessive-compulsive disorder. NeuroImage 2012, 59:1461-1468.
89. Nehlig A., Daval J.L., Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res. Brain Res. Rev. 1992, 17:139-170.
90. Nguyen T.V., Brownell A.L., Iris Chen Y.C., Livni E., Coyle J.T., Rosen B.R., Cavagna F., Jenkins B.G. Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse 2000, 36:57-65.
91. Northoff G., Walter M., Schulte R.F., Beck J., Dydak U., Henning A., Boeker H., Grimm S., Boesiger P. GABA concentrations in the human anterior cingulate cortex predict negative BOLD responses in fMRI. Nat. Neurosci. 2007, 10:1515-1517.
92. Ogawa S., Tank D.W., Menon R., Ellermann J.M., Kim S.-G., Merkle H., Ugurbil K. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:5951-5955.
93. Palacios J.M., Mengod G., Vilaro M.T., Ramm P. Recent trends in receptor analysis techniques and instrumentation. J. Chem. Neuroanat. 1991, 4:343-353.
94. Perese D.A., Ulman J., Viola J., Ewing S.E., Bankiewicz K.S. A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res. 1989, 494:285-293.
95. Phelps M.E., Hoffman E.J., Huang S.C., Kuhl D.E. Positron tomography: "in vivo" autoradiographic approach to measurement of cerebral hemodynamics and metabolism. Acta Neurol. Scand. Suppl. 1977, 64:446-447.
96. Pompeiano M., Palacios J.M., Mengod G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J. Neurosci. 1992, 12:440-453.
97. Rabinak C.A., Sripada C.S., Angstadt M., de Wit H., Phan K.L. Cannabinoid modulation of subgenual anterior cingulate cortex activation during experience of negative affect. J. Neural Transm. 2011, (Electronic publication ahead of print).
98. Rabiner E.A., Beaver J., Makwana A., Searle G., Long C., Nathan P.J., Newbould R.D., Howard J., Miller S.R., Bush M.A., Hill S., Reiley R., Passchier J., Gunn R.N., Matthews P.M., Bullmore E.T. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Mol. Psychiatry 2011, 16(826-835):785.
99. Raichle M.E., Grubb R.L., Gado M.H., Eichling J.O., Ter-Pogossian M.M. Correlation between regional cerebral blood flow and oxidative metabolism. In vivo studies in man. Arch. Neurol. 1976, 33:523-526.
100. Rauch A., Rainer G., Augath M., Oeltermann A., Logothetis N.K. Pharmacological MRI combined with electrophysiology in non-human primates: effects of lidocaine on primary visual cortex. NeuroImage 2008, 40:590-600.
101. Ren J., Xu H., Choi J.K., Jenkins B.G., Chen Y.I. Dopaminergic response to graded dopamine concentration elicited by four amphetamine doses. Synapse 2009, 63:764-772.
102. Sato A., Sato Y. Cholinergic neural regulation of regional cerebral blood flow. Alzheimer Dis. Assoc. Disord. 1995, 9:28-38.
103. Scanley B.E., Kennan R.P., Gore J.C. Changes in rat cerebral blood volume due to modulation of the 5-HT(1A) receptor measured with susceptibility enhanced contrast MRI. Brain Res 2001, 913:149-155.
104. Schalling M., Dagerlind A., Goldstein M., Ehrlich M., Greengard P., Hokfelt T. Comparison of gene expression of the dopamine D-2 receptor and DARPP-32 in rat brain, pituitary and adrenal gland. Eur. J. Pharmacol. 1990, 188:277-281.
105. Schwarz A.J., Zocchi A., Reese T., Gozzi A., Garzotti M., Varnier G., Curcuruto O., Sartori I., Girlanda E., Biscaro B., Crestan V., Bertani S., Heidbreder C., Bifone A. Concurrent pharmacological MRI and in situ microdialysis of cocaine reveal a complex relationship between the central hemodynamic response and local dopamine concentration. NeuroImage 2004, 23:296-304.
106. Schwarz A.J., Gozzi A., Reese T., Bifone A. In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI. NeuroImage 2007, 34:1627-1636.
107. Schwarz A.J., Gozzi A., Reese T., Heidbreder C.A., Bifone A. Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d-amphetamine modified by selective dopamine D3 receptor antagonist SB277011A. Magn. Reson. Imaging 2007, 25:811-820.
108. Schwarz A.J., Gozzi A., Bifone A. Community structure in networks of functional connectivity: resolving functional organization in the rat brain with pharmacological MRI. NeuroImage 2009, 47:302-311.
109. Schweinhardt P., Bountra C., Tracey I. Pharmacological FMRI in the development of new analgesic compounds. NMR Biomed. 2006, 19:702-711.
110. Sekar S., Verhoye M., Van Audekerke J., Vanhoutte G., Lowe A.S., Blamire A.M., Steckler T., Van der Linden A., Shoaib M. Neuroadaptive responses to citalopram in rats using pharmacological magnetic resonance imaging. Psychopharmacology (Berl) 2011, 213:521-531.
111. Sell L.A., Simmons A., Lemmens G.M., Williams S.C., Brammer M., Strang J. Functional magnetic resonance imaging of the acute effect of intravenous heroin administration on visual activation in long-term heroin addicts: results from a feasibility study. Drug Alcohol Depend. 1997, 49:55-60.
112. Shih Y.Y., Chen C.C., Shyu B.C., Lin Z.J., Chiang Y.C., Jaw F.S., Chen Y.Y., Chang C. A new scenario for negative functional magnetic resonance imaging signals: endogenous neurotransmission. J. Neurosci. 2009, 29:3036-3044.
113. Shmuel A., Yacoub E., Pfeuffer J., Van de Moortele P.F., Adriany G., Hu X., Ugurbil K. Sustained negative BOLD, blood flow and oxygen consumption response and its coupling to the positive response in the human brain. Neuron 2002, 36:1195-1210.
114. Shmuel A., Augath M., Oeltermann A., Logothetis N.K. Negative functional MRI response correlates with decreases in neuronal activity in monkey visual area V1. Nat. Neurosci. 2006, 9:569-577.
115. Silva A.D., Zhang W., Williams D.S., Koretsky A.P. Multislice MRI of Rat Brain During Amphetamine Stimulation Using Arterial Spin Labelling 1995, Magn. Reson, Med, 33.
116. Snoussi K., Bulte J.W., Gueron M., van Zijl P.C. Sensitive CEST agents based on nucleic acid imino proton exchange: detection of poly(rU) and of a dendrimer-poly(rU) model for nucleic acid delivery and pharmacology. Magn. Reson. Med. 2003, 49:998-1005.
117. Sorg O., Magistretti P.J. Characterization of the glycogenolysis elicited by vasoactive intestinal peptide, noradrenaline and adenosine in primary cultures of mouse cerebral cortical astrocytes. Brain Res 1991, 563:227-233.
118. Stein E.A., Pankiewicz J., Harsch H.H., Cho J.K., Fuller S.A., Hoffmann R.G., Hawkins M., Rao S.M., Bandettini P.A., Bloom A.S. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am. J. Psychiatry 1998, 155:1009-1015.
119. Stella N., Tence M., Glowinski J., Premont J. Glutamate-evoked release of arachidonic acid from mouse brain astrocytes. J. Neurosci. 1994, 14:568-575.
120. Stullken E.H., Milde J.H., Michenfelder J.D., Tinker J.H. The nonlinear responses of cerebral metabolism to low concentrations of halothane, enflurane, isoflurane, and thiopental. Anesthesiology 1977, 46:28-34.
121. Tayebati S.K., Lokhandwala M.F., Amenta F. Dopamine and vascular dynamics control: present status and future perspectives. Curr. Neurovasc. Res. 2011, 8:246-257.
122. Telang F.W., Volkow N.D., Levy A., Logan J., Fowler J.S., Felder C., Wong C., Wang G.J. Distribution of tracer levels of cocaine in the human brain as assessed with averaged [11C]cocaine images. Synapse 1999, 31:290-296.
123. Tomasi D., Volkow N.D., Wang R., Carrillo J.H., Maloney T., Alia-Klein N., Woicik P.A., Telang F., Goldstein R.Z. Disrupted functional connectivity with dopaminergic midbrain in cocaine abusers. PLoS One 2010, 5:e10815.
124. Tracey I. Can neuroimaging studies identify pain endophenotypes in humans?. Nat. Rev. Neurol. 2011, 7:173-181.
125. Upadhyay J., Anderson J., Schwarz A.J., Coimbra A., Baumgartner R., Pendse G., George E., Nutile L., Wallin D., Bishop J., Neni S., Maier G., Iyengar S., Evelhoch J.L., Bleakman D., Hargreaves R., Becerra L., Borsook D. Imaging drugs with and without clinical analgesic efficacy. Neuropsychopharmacology 2011, 36:2659-2673.
126. Upadhyay J., Pendse G., Anderson J., Schwarz A.J., Baumgartner R., Coimbra A., Bishop J., Knudsen J., George E., Grachev I., Iyengar S., Bleakman D., Hargreaves R., Borsook D., Becerra L. Improved characterization of BOLD responses for evoked sensory stimuli. NeuroImage 2010, 49:2275-2286.
127. van Hell H.H., Bossong M.G., Jager G., Kahn R.S., Ramsey N.F. Methods of the pharmacological imaging of the cannabinoid system (PhICS) study: towards understanding the role of the brain endocannabinoid system in human cognition. Int. J. Methods Psychiatr. Res. 2011, 20:10-27.
128. Vaucher E., Linville D., Hamel E. Cholinergic basal forebrain projections to nitric oxide synthase-containing neurons in the rat cerebral cortex. Neuroscience 1997, 79:827-836.
129. Wink A.M., Bernard F., Salvador R., Bullmore E., Suckling J. Age and cholinergic effects on hemodynamics and functional coherence of human hippocampus. Neurobiol. Aging 2006, 27:1395-1404.
130. Winton-Brown T.T., Allen P., Bhattacharyya S., Borgwardt S.J., Fusar-Poli P., Crippa J.A., Seal M.L., Martin-Santos R., Ffytche D., Zuardi A.W., Atakan Z., McGuire P.K. Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacology 2011, 36:1340-1348.
131. Wu Y., Evbuomwan M., Melendez M., Opina A., Sherry A.D. Advantages of macromolecular to nanosized chemical-exchange saturation transfer agents for MRI applications. Future Med. Chem. 2010, 2:351-366.
132. Xi Z.X., Wu G., Stein E.A., Li S.J. GABAergic mechanisms of heroin-induced brain activation assessed with functional MRI. Magn. Reson. Med. 2002, 48:838-843.
133. Xi Z.X., Wu G., Stein E.A., Li S.J. Opiate tolerance by heroin self-administration: an fMRI study in rat. Magn. Reson. Med. 2004, 52:108-114.
134. Xu H., Li S.J., Bodurka J., Zhao X., Xi Z.X., Stein E.A. Heroin-induced neuronal activation in rat brain assessed by functional MRI. Neuroreport 2000, 11:1085-1092.
135. Zaharchuk G., Mandeville J.B., Bogdanov A.A., Weissleder R., Rosen B.R., Marota J.J. Cerebrovascular dynamics of autoregulation and hypoperfusion. An MRI study of CBF and changes in total and microvascular cerebral blood volume during hemorrhagic hypotension. Stroke 1999, 30:2197-2204. discussion 2204-2195.
136. Zhang Z., Andersen A.H., Avison M.J., Gerhardt G.A., Gash D.M. Functional MRI of apomorphine activation of the basal ganglia in awake rhesus monkeys. Brain Res 2000, 852:290-296.
137. Zhang Z., Andersen A., Grondin R., Barber T., Avison R., Gerhardt G., Gash D. Pharmacological MRI mapping of age-associated changes in basal ganglia circuitry of awake rhesus monkeys. NeuroImage 2001, 14:1159-1167.